Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

EVALUATION OF TWO MIDWIFE-SUPPORTED BREASTFEEDING POSITIONS DURING THE FIRST BREASTFEEDING FOLLOWING VAGINAL BIRTH

NCT07864753 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-06-01
Last updated
2026-10-08

Condition(s) studied

Breastfeeding InitiationMidwifery SupportBreastfeeding Support

Investigational drug(s) / intervention(s)

Midwife-Supported Modified Football Hold GroupMidwife-Supported Cradle Hold Group

Midwife-Supported Modified Football Hold Group: Intervention Description Participants randomized to the modified football hold group will receive standardized midwife-supported breastfeeding assistance during the first breastfeeding session after vaginal birth. The mother will be positioned in a comfortable supine position with appropriate pillow support as needed. The infant will be positioned nearly perpendicular to the mother's torso, with the feet directed toward the mother's shoulder and the head aligned with the breast. The attending midwife will support the infant's head to facilitate proper latch while stabilizing the infant's back and hips to promote effective breastfeeding. Continuous guidance on positioning and attachment will be provided throughout the first breastfeeding session. Participants randomized to the cradle hold group will receive standardized midwife-supported breastfeeding assistance using the cradle hold during the first breastfeeding session after vaginal birth. The mother will be positioned in a semi-up

Midwife-Supported Cradle Hold Group: Participants assigned to this arm will receive standardized midwife-supported breastfeeding using the cradle hold position during the first breastfeeding session after vaginal birth. Mothers will be positioned in a semi-upright or upright sitting position, while infants will be placed parallel to the mother's body with appropriate head, back, and hip support. The midwife will provide standardized guidance to ensure correct positioning and effective latch throughout the breastfeeding session. Outcomes will be assessed immediately after completion of the first breastfeeding session.

Study summary

This study is being conducted by Dr. Benay OĞUZ. This form has been prepared to inform you about the conditions and procedures of the study.

\*\*Title of the Study:\*\* Evaluation of Two Different Midwife-Supported Breastfeeding Positions During the First Breastfeeding After Vaginal Birth: A Randomized Controlled Trial

\*\*What Is the Purpose of the Study?\*\* The purpose of this study is to evaluate the effects of two different breastfeeding positions, applied with midwife support during the first breastfeeding after vaginal birth, on breastfeeding success. If you agree to participate in the study, you will be expected to allow the midwife to support you during breastfeeding. Your participation in this study will take approximately 20 minutes.

\*\*How Will We Use the Information Collected from You?\*\* Your participation in this study is entirely voluntary. You will not be asked to provide any information that could identify you or your institution. Your information will be kept strictly confidential and will be evaluated only by the researchers. The information obtained from the participants will be analyzed collectively and may be used in scientific publications. The data you provide will not be matched with any identifying information collected through the voluntary participation forms.

Approximately 80 postpartum women who voluntarily agree to participate are expected to be included in this study.

\*\*What You Should Know About Participation:\*\* This study does not involve any additional risks beyond those that may ordinarily be encountered in daily life. The intervention consists of midwife-supported breastfeeding positioning, which is part of routine postpartum care, and observational assessment of breastfeeding.

Midwife support during the first breastfeeding may contribute to improving maternal comfort and reducing breastfeeding difficulties in the early postpartum period by facilitating more effective positioning.

If you feel uncomfortable for any reason during your participation, you are free to withdraw from the study at any time. In such a case, it will be sufficient to inform the researcher verbally or by email that you wish to withdraw from the study. At the end of the study, any questions you may have regarding the research will be answered.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Women aged 18 years or older * Vaginal singleton birth at 37-42 weeks of gestation * Healthy newborn with an Apgar score ≥7 at 5 minutes * Mother and newborn clinically stable and eligible for breastfeeding * First breastfeeding initiated in the study hospital * Ability to communicate in Turkish * Willingness to participate and provision of written informed consent Exclusion Criteria: * Cesarean birth * Multiple pregnancy * Preterm birth (\<37 weeks) or post-term birth (\>42 weeks) * Newborn requiring admission to the neonatal intensive care unit * Congenital anomalies or medical conditions affecting breastfeeding * Maternal conditions contraindicating breastfeeding, such as severe postpartum complications or other medical contraindications * Maternal or neonatal condition preventing the first breastfeeding session * Refusal or withdrawal of informed consent

Primary outcome measure(s)

  • Breastfeeding Success — Immediately after completion of the first breastfeeding session, within the first 1 hour after vaginal birth.
    Breastfeeding success will be assessed using the LATCH Breastfeeding Assessment Tool immediately after completion of the first breastfeeding session following vaginal birth. Total scores range from 0 to 10, with higher scores indicating better breastfeeding success.

Trial sites (1)

FacilityCityRegionStatus
Izmir Bakircay University Cigli Training and Research Hospital İzmir Balıkesir
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07864753 on ClinicalTrials.gov ↗ ← All trials in Turkey